This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
U.S. Equities Lag International in 2025: 5 Top ETF Performers
by Sanghamitra Saha
International ETFs like FDT, IDV, FDTS, EFAS & FLEU soared as investors pivot from pricey and uncertain policy-driven U.S. markets to undervalued international plays.
Zacks Investment Ideas feature highlights S&P 500
by Zacks Equity Research
S&P 500 have been highlighted in this Investment Ideas article.
November Pullback Underway: Here's What to Know
by Bryan Hayes
The latest bearish headlines point to hefty AI valuations. But here's why this bull market likely still has some legs.
Fearing AI Valuation Concerns? Tap 3 High-Dividend ETFs
by Sanghamitra Saha
Fearing AI valuation risks? Seek stability in dividends. ETFs like SDEM, DVYE & LVHI are shining with strong yields and recent gains.
Worried About an AI Bubble? Look to Surging International Stocks
by Neena Mishra
We spotlight three international ETFs that are outperforming the S&P 500 by a wide margin.
Biotech ETFs Hovering Around a 52-Week: Here's Why
by Sanghamitra Saha
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
Russell 2000 Beats S&P 500 Over Past 6 Months: ETFs in Focus
by Sanghamitra Saha
Small caps rebounded lately. ETFs like IWM, FESM, VTWO & more outpaced SPY in 6 months as rate-cut hopes and easing tariffs fueled momentum.
Bank ETFs in Red Over the Past Month: Pain or Gain Ahead? (Revised)
by Sanghamitra Saha
Bank ETFs like IYG, IYF, KBWB, XLF and VFH dip on credit jitters. Are gains ahead as Q3 earnings & a steepening yield curve offer hope?
Bank ETFs in Red Over the Past Month: Pain or Gain Ahead?
by Sanghamitra Saha
Bank ETFs like IYG, IYF, KBWB, XLF and VFH dip on credit jitters. Are gains ahead as Q3 earnings & a steepening yield curve offer hope?
Biotech ETFs Bounce Back in 2025: Here's Why
by Sanghamitra Saha
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.